NuCana plc (NCNA)
| Market Cap | 7.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.98M |
| Shares Out | 2.09M |
| EPS (ttm) | -16.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,480 |
| Open | 3.700 |
| Previous Close | 3.790 |
| Day's Range | 3.400 - 3.820 |
| 52-Week Range | 3.400 - 23.750 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+31.23%) |
| Earnings Date | May 15, 2024 |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil th... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for NCNA stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 31.23% from the latest price.
News
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death
NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (...
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety
NuCana to Present at TD Cowen's 44th Annual Health Care Conference
EDINBURGH, United Kingdom, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data
NuCana Announces Listing Transfer to Nasdaq Capital Market
EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Department ...
NuCana to Present at the Jefferies London Healthcare Conference
EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host on...
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Ca...
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023
NuCana to Present at the Jefferies Healthcare Conference
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present...
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ...
NuCana Announces Receipt of Nasdaq Notice
EDINBURGH, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nas...
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer Ac...
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Multiple Important Data Readouts Expected in 2023
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid
Ruling Has No Impact on NuCana's Anti-Cancer ProTide Patents Ruling Has No Impact on NuCana's Anti-Cancer ProTide Patents
NuCana to Participate in Two Upcoming Investor Conferences
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will partici...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) f...
NuCana Announces Receipt of NASDAQ Notice
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Na...
NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update
Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023
NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells
NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors
NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022
EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held Septemb...